EN DE

PharmaEngine (4162) Fair Value & Analysis

Healthcare · TW · Market cap 9.8B TWD (≈ $309M) · ISIN TW0004162003

What is PharmaEngine really worth?

P PharmaEngine 4162 · TWO
Price57.80 TWD
Fair Value48.43 TWD
Upside−16.2%
Quality74/100

A solid business, but trading 19% above our fair value of 48.43 TWD.

As of Aug 27, 2026, the fair value of PharmaEngine is 48.43 TWD per share against a price of 57.80 TWD, so the fair value sits 16% below the price. A model estimate blended from multiple valuation models, recalculated regularly.

Watch PharmaEngine for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

Strengths

✓Highly profitable · 43.8% net margin
✓generates free cash flow
✓Ranks above peers (9/13)
✓Wide moat 74/100

Risks

!Weak Growth (revenue 5y −2.9 %/yr)
!Weak on valuation: 12 out of 100

For context

·3.46% dividend yield
Evidence: High Range 37.82 TWD – 59.04 TWD

Fair value as of: Aug 27, 2026

From 25 valuation models · updated 10 days ago

Share price −6.8% over the past month.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

  • A high-quality business (quality 74/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
  • The price sits in the upper half of our model range, so the margin of safety is thin.
  • The data supports the verdict: every model runs on fully documented inputs.

Price vs Fair Value (5 years)

129.15 TWD 45.86 TWD Fair Value 48.43 TWD Mar 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 27, 2026.

How to read this chart

60‑month range 45.86 TWD – 129.15 TWD · fair‑value band 37.82 TWD – 59.04 TWD · the 57.80 TWD price screens above the 48.43 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 27, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

PharmaEngine (4162) currently trades at 57.80 TWD, while our model-based Fair Value estimate is 48.43 TWD, implying the stock looks roughly 19.3% overvalued today. The Quality Score stands at 74/100 (solid quality), in the Healthcare sector. Bull case: the Growth DCF group reads highest at a median of 333.70 TWD per share, and 17 of the 25 models we run sit above the 57.80 TWD price. Bear case: the Asset-Based group reads lowest at 22.97 TWD, and 8 of the 25 models stay below the price. Evidence for this calculation is high.

Over the trailing twelve months, PharmaEngine generated revenue of 911M TWD at a net margin of 42.5%. Revenue declined 84.8% year over year. It earns a return on equity of 7.5%. The balance sheet holds a net cash position of 861M TWD. Fundamentals as of Aug 27, 2026

Our scenario range runs from 37.82 TWD (bear case) to 59.04 TWD (bull case); at 57.80 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 24% below its 52-week high and 9% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −56% fair-value upside, at −16%, 4162 screens cheaper than that median.

Fair Value models

This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly 0.4707 TWD per share, which is 1.0 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Residual Income best evidence 28.33 TWD 30.27 TWD 33.03 TWD 76
FCF DCF 202.15 TWD 305.30 TWD 626.89 TWD 74
5Y EBITDA Exit 88.62 TWD 122.86 TWD 187.95 TWD 72
All 25 models by family
DCF Models
FCF DCF 202.15 TWD 305.30 TWD 626.89 TWD 74
Owner Earnings 52.09 TWD 102.04 TWD 203.05 TWD 69
5Y Revenue Exit 75.78 TWD 96.65 TWD 137.22 TWD 71
5Y EBITDA Exit 88.62 TWD 122.86 TWD 187.95 TWD 72
5Y P/E Exit 97.89 TWD 167.36 TWD 255.31 TWD 67
10Y Revenue Exit 113.64 TWD 172.50 TWD 195.01 TWD 66
10Y EBITDA Exit 123.33 TWD 199.02 TWD 318.99 TWD 64
10Y P/E Exit 129.91 TWD 218.18 TWD 357.04 TWD 60
Earnings-Based
Graham-Dodd 18.35 TWD 127.94 TWD 179.55 TWD 63
Lynch FV 45.89 TWD 65.56 TWD 85.23 TWD 61
PEG = 1.0 45.89 TWD 65.56 TWD 85.23 TWD 57
EPV 33.94 TWD 37.55 TWD 40.68 TWD 70
Dividend Discount
Gordon GGM 52.69 TWD 104.98 TWD 158.97 TWD 67
DDM Multi-Stage 52.69 TWD 90.73 TWD 110.82 TWD 67
Multiples
P/E Multiple 44.52 TWD 59.36 TWD 74.19 TWD 63
P/S Multiple 16.65 TWD 22.20 TWD 27.75 TWD 58
P/B Multiple 34.40 TWD 45.87 TWD 57.33 TWD 55
EV/EBIT 48.78 TWD 61.36 TWD 73.95 TWD 63
EV/EBITDA 42.85 TWD 53.46 TWD 64.07 TWD 64
EV/Revenue 24.34 TWD 30.05 TWD 35.76 TWD 52
Asset-Based
NCAV (Graham) 17.14 TWD 22.97 TWD 34.28 TWD 51
Growth DCF
Growth DCF 190.52 TWD 333.70 TWD 613.92 TWD 72
Economic Profit
Residual Income best evidence 28.33 TWD 30.27 TWD 33.03 TWD 76
ROIC Compounder 33.94 TWD 42.21 TWD 50.45 TWD 70
Growth Earnings
Growth-Adj P/E 60.49 TWD 86.42 TWD 112.34 TWD 67

Widest divergence: Growth DCF (333.70 TWD) versus Asset-Based (22.97 TWD). Highest evidence: Residual Income (76).

Notify me when 4162 reaches fair value

Put 4162 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 21.5
P/S ratio 9.14 P/E × margin
EPS (TTM) 2.69 TWD price ÷ EPS = P/E 21.5
Dividend yield 3.5% payout 74.3%
Net margin 42.5% FY2025
Return on equity 7.5% TTM
More key figures
Profitability
Return on assets (EBIT) 14.8% avg 5y
Operating margin 41.7% TTM
Growth
Revenue (TTM) 911M TWD TTM
Revenue growth (YoY) −84.8% 3y avg +11.7%
EPS growth (YoY) −90.7%
Balance sheet & cash flow
Free cash flow 1.7B TWD FY2025
Net cash 861M TWD FY2023

Figures from reported company fundamentals · as of Aug 27, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 74/100

Of which business quality 74 · Market factors (momentum, volatility) 46

Profitability 45
Margins and returns on capital today
Quality Growth 22
Are margins and returns improving?
Cashflow 100
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 71
Disciplined investing over empire-building
Low Volatility 84
Calm price path (market factor)
Momentum 36
Price trend over the last 3–12 months (market factor)
52W Momentum 19
Distance to the 52-week high (market factor)
Net Issuance 91
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells.

Full company description

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is also developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

PharmaEngine reported revenue of 911M TWD in FY2025 versus 655M TWD in FY2021, a compound +8.6%/yr. Reported net income was 388M TWD in FY2025, compounding −2.3%/yr from FY2021.

Growth Quality 40/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
911M TWD
Latest YoY
−63.9%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+11.7%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−2.9%
Avg. revenue growth/yr (14Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+7.8%
Value creation/yr (5Y, in TWD) ⓘEarnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+2.0% · in TWD
Earnings growth per share plus dividend yield: the value created per share and year.
Earnings growth per share−1.5%
Dividend yield3.5%
Trend ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.5Y −1.5% vs 10Y 0.3%, steady
Operating margin (EBIT) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.71.3% (2020) → 46.7% (2025) · falling
Worst earnings drop133% (2013) (loss year, drop beyond 100%) · in TWD
Revenue +8.6%/yr
FY21 655M TWD
FY22 654M TWD
FY23 768M TWD
FY24 2.5B TWD
FY25 911M TWD
Net income −2.3%/yr
FY21 426M TWD
FY22 319M TWD
FY23 275M TWD
FY24 1.8B TWD
FY25 388M TWD
Character of growth · EPS growth decomposed (2012-2023) +15.7 % p.a.
Revenue per share +13.6 %

of which total revenue +14.4 % · buybacks/dilution −0.7 %

EBIT margin +8.1 %
Tax rate −2.4 %
Residual (interest, one-offs) −3.5 %

Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).

4162 screens 19% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

PharmaEngine · Fair Value
48.43 TWD −19%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "PharmaEngine Fair Value". https://www.fairvalue-calculator.com/stock/4162.TWO

Peer Group

Biotechnology · 627 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 74 · Top 25%
Fair Value upside −16% · Above median
Return on equity (TTM) 8% · Top 25%
Return on assets 5% · Top 25%
Net margin (TTM) 44% · Top 25%
Operating margin (TTM) 54% · Top 25%
Revenue growth 28% · Top 25%
Dividend yield (TTM) 3.5% · Above median

Valuation Multiples vs Biotechnology median · lower = cheaper

P/E (TTM) 21.5× · Cheaper than median
P/B 1.98× · Pricier than median
P/S (TTM) 10.14× · Pricier than 75% of peers
P/FCF 0.2× · Cheaper than 75% of peers
EV/EBITDA 17.5× · Pricier than median

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE12 · sector 0
FUTURE100 · sector 0
PAST32 · sector 0
HEALTH0 · sector 98
DIVIDEND69 · sector 26

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 27, 2026).

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $547.55 $278.78 −49%
Regeneron Pharmaceuticals, Inc REGN $807.71 $594.40 −26%
argenx SE ARGX €877.60 €292.84 −67%
BeOne Medicines AG 688235 ¥271.00 ¥47.36 −83%
Samsung Biologics Co 207940 1,518,000 KRW 1,055,793 KRW −30%
Alnylam Pharmaceuticals, Inc ALNY $228.61 $51.70 −77%
Royalty Pharma plc RPRX $60.58 $24.22 −60%
Celltrion, Inc 068270 190,700 KRW 74,519 KRW −61%
BioNTech SE BNTX $103.76 $45.70 −56%
Incyte Corporation INCY $123.22 $115.79 −6%

Compare PharmaEngine with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Extrinsic Value Calculator (Options) Splits an option premium into intrinsic and extrinsic (time) value. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is PharmaEngine (4162) overvalued or undervalued?
As of Aug 27, 2026, our model estimates a fair value of 48.43 TWD versus a price of 57.80 TWD, about −16% upside (overvalued).
What is the fair value of 4162?
Our model-based fair value for PharmaEngine is 48.43 TWD (as of Aug 27, 2026), built from audited fundamentals. The current price: 57.80 TWD.
What is the quality score of 4162?
PharmaEngine has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PharmaEngine (4162)?
Our model-based price target is the fair value of 48.43 TWD (as of Aug 27, 2026) from 25 valuation models. Cautious scenario 37.82 TWD, optimistic scenario 59.04 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the PharmaEngine stock forecast for 2026?
Our models put fair value at 48.43 TWD, about −16% upside versus a price of 57.80 TWD (overvalued). Cautious scenario 37.82 TWD, optimistic scenario 59.04 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of PharmaEngine (4162)?
PharmaEngine reported trailing-twelve-month revenue of about 911M TWD (latest available figure, as of Aug 27, 2026).
What is the net profit margin of 4162?
The net profit margin of PharmaEngine is about 42.5%, meaning it keeps roughly 42.5% of revenue as net income. Based on the latest reported figures.
Does PharmaEngine pay a dividend?
PharmaEngine currently shows a dividend yield of about 3.46% relative to its recent price (as of Aug 27, 2026).
Free · no account needed

Watch PharmaEngine in the live analysis

One click puts PharmaEngine on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.